Prognosis
Fake Ozempic Seized by FDA as Demand for Obesity Drugs Soars
- FDA warns against use of counterfeit versions of drug
- Europe’s drug regulator has also raised concern over fakes
This article is for subscribers only.
The US Food and Drug Administration has seized thousands of units of counterfeit Ozempic, Novo Nordisk A/S’s diabetes drug that’s been adapted into a blockbuster weight-loss treatment, and warned against using them.
The regulator advised wholesalers, retail pharmacies, health care practitioners and patients to check the product they have received and not distribute or sell products labeled with lot number NAR0074 and serial number 430834149057.